PT-141 Dosage and Protocols
PT-141 dosage protocols reported in published research, plus reconstitution and storage.
Clinical Dosing Constraints and the Effect-Duration Paradox
The FDA-approved prescribing information for Vyleesi includes specific pharmacokinetic-informed dosing restrictions that reflect the disconnect between half-life and duration of activity. • Administration is limited to no more than one dose per 24 hours and no more than 8 doses per month, despite the 2.7-hour half-life. These restrictions are based on clinical trial safety data showing that transient blood pressure increases (10-15 mmHg systolic) and nausea warrant a full 24-hour washout period between doses. • Onset of sexual desire effects begins within 30-60 minutes of injection — closely tracking the Tmax — but effects on desire and arousal persist for up to 24 hours, consistent with sustained MC4R signaling in hypothalamic circuits after the peptide has cleared from plasma. • The peptide should be administered at least 45 minutes before anticipated sexual activity. Unlike PDE5 inhibitors which require vascular arousal mechanisms, PT-141's central mechanism means the timing window is more flexible — the 24-hour effect window does not require precise timing.
Dosing Summary
Dosing details above reflect FDA-approved labeling and/or published clinical protocols. Always refer to the official drug label (linked above) for approved prescribing details, contraindications, and warnings.
Reported protocol doses
Reconstitution
A 10mg vial with 5mL of bacteriostatic water is the pairing reported most often. 10mg vial + 5mL bacteriostatic water = 2mg/mL. A 1mg dose is 0.5mL (50 units), taken 45 min to a few hours before activity.
Work out your own concentration with the reconstitution calculator.
Doses shown are those reported in published research, not a recommendation.
References
- Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder · Kingsberg SA, et al. · 2019
- Kingsberg SA, et al. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials. Obstet Gynecol. 2019;134(5):899-908. · Kingsberg SA, Clayton AH, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Simon JA · 2019
- Safety Profile of Bremelanotide Across the Clinical Development Program. · Clayton AH, Kingsberg SA, Portman D et al. · 2022
- The neurobiology of bremelanotide for the treatment of hypoactive ... · Pfaus JG, Sadiq A, Spana C, Clayton AH · 2022
- Clayton AH, et al. Long-term safety and efficacy of bremelanotide for hypoactive sexual desire disorder. Obstet Gynecol. 2019;134(5):909-917. · Simon JA, Kingsberg SA, Portman D, Williams LA, Krop J, Jordan R, Lucas J, Clayton AH · 2019
- Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. · Simon JA, Kingsberg SA, Portman D et al. · 2022